A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer

Inglebert, Marine; Dettwiler, Martina; Hahn, Kerstin; Letko, Anna; Drögemüller, Cord; Doench, John; Brown, Adam; Memari, Yasin; Davies, Helen; Degasperi, Andrea; Nik-Zainal, Serena; Rottenberg, Sven (2022). A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer (bioRxiv). Cold Spring Harbor Laboratory 10.1101/2022.09.02.505845

	Text revised_manuscript_Inglebert_A_living_biobank_of_canine_mammary_tumor_organoids_as_a_comparative_model_for_human_breast_cancer.pdf - Accepted Version Restricted to registered users only Available under License Publisher holds Copyright. Download (6MB) | Request a copy
Preview	Text 2022.09.02.505845v1.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

Mammary tumors in dogs hold great potential as naturally occurring breast cancer models in translational oncology, as they share the same environmental risk factors, key histological features, hormone receptor expression patterns, prognostic factors, and genetic characteristics as their human counterparts. We aimed to develop in vitro tools that allow functional analysis of canine mammary tumors (CMT), as we have a poor understanding of the underlying biology that drives the growth of these heterogeneous tumors. We established the long-term culture of 24 organoid lines from 16 dogs, including organoids derived from normal mammary epithelium or benign lesions. CMT organoids recapitulated key morphological and immunohistological features of the primary tissue from which they were derived, including hormone receptor status. Furthermore, genetic characteristics (driver gene mutations, DNA copy number variations, and single-nucleotide variants) were conserved within tumor-organoid pairs. We show how CMT organoids are a suitable model for in vitro drug assays and can be used to investigate whether specific mutations predict therapy outcomes. Specifically, certain CMT subtypes, such as PIK3CA mutated, estrogen receptor-positive simple carcinomas, can be valuable in setting up a preclinical model highly relevant to human breast cancer research. In addition, we could genetically modify the CMT organoids and use them to perform pooled CRISPR/Cas9 screening, where library representation was accurately maintained. In summary, we present a robust 3D in vitro preclinical model that can be used in translational research, where organoids from normal, benign as well as malignant mammary tissues can be propagated from the same animal to study tumorigenesis.

Interest & Impact

Downloads

17 since deposited on 04 Oct 2022
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item